Novo-Nordisk A/S (NVO) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and m...
Novo-Nordisk A/S's revenue increased 6.4% year over year, from $290.40B to $309.06B.
Net income increased 1.4% over the same period, from $100.99B to $102.43B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 120% in total.
Total debt increased by 27.4% to $130.96B.
The debt-to-equity ratio stands at 0.67, indicating a moderate leverage profile.
Novo-Nordisk A/S maintains a strong net profit margin of 33.1%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $140.80B | $47.76B | $117.14B | $58.64B | N/A | $194.51B | $26.64B | $70.75B |
| FY2022 | $176.95B+25.7% | $55.52B | $148.51B | $74.81B | N/A | $241.26B | $25.78B | $83.49B |
| FY2023 | $232.26B+31.3% | $83.68B | $196.50B | $102.57B | N/A | $314.49B | $27.01B | $106.56B |
| FY2024 | $290.40B+25.0% | $100.99B | $245.88B | $128.34B | N/A | $465.63B | $102.79B | $143.49B |
| FY2025 | $309.06B+6.4% | $102.43B | $250.28B | $127.66B | N/A | $542.90B | $130.96B | $194.05B |
Balance Sheet Summary (Latest Period)
Total Assets
$542.90B
Total Liabilities
$348.86B
Total Equity
$194.05B
Cash & Equivalents
$26.96B
Total Debt
$130.96B
Current Assets
$172.45B
Current Liabilities
$215.66B
Retained Earnings
$195.30B